Aquestive Therapeutics To Take A Leap With New Seizures clusters Drug

Earnings Per Share AQST has a market cap of $304 and an EPS of -1.76. While its historical trading records might not be glowing, its outlook is promising. Its current stock price is $9.05 and a peak of $33 is projected in a year from now. The recommendation is Strong Buy for AQST Other AQST had been in the news recently when it announced FDA’s decision to accept an NDA for its refractory and seizure clusters treatment called Libervant. The Prescription Drug User Fee Act review date is Month -end September 2020. A medical comparison of AQST’s with a recently approved cluster seizure medication in January, the VALTOCO and two other available options showed that the AQST has a proven therapeutic value otherwise it would not have got a waiver over the expected 7-year exclusivity period given to VALTOCO. Libervant sterling projection as the first diazepam product to be nationally available for to ARRS patients, opens a possible $300 million revenue outlook for AQST. Earnings Growth It will be right to consider Libervant is a buy-stock right now with market analysts accepting that it could do a 300-percent move over a 12 -month period after its launch

back

Aquestive Therapeutics To Take A Leap With New Seizures clusters Drug

Sep 21, 2020

bullish

fundamentals Analysis

[1 min Read]

Earnings Per Share AQST has a market cap of $304 and an EPS of -1.76. While its historical trading records might not be glowing, its outlook is promising. Its current stock price is $9.05 and a peak of $33 is projected in a year from now. The recommendation is Strong Buy for AQST Other AQST had been in the news recently when it announced FDA’s decision to accept an NDA for its refractory and seizure clusters treatment called Libervant. The Prescription Drug User Fee Act review date is Month -end September 2020. A medical comparison of AQST’s with a recently approved cluster seizure medication in January, the VALTOCO and two other available options showed that the AQST has a proven therapeutic value otherwise it would not have got a waiver over the expected 7-year exclusivity period given to VALTOCO. Libervant sterling projection as the first diazepam product to be nationally available for to ARRS patients, opens a possible $300 million revenue outlook for AQST. Earnings Growth It will be right to consider Libervant is a buy-stock right now with market analysts accepting that it could do a 300-percent move over a 12 -month period after its launch
page loading card

AQST

Aquestive Therapeutics, Inc.

0.64

0.01
0.79%

Return

-92.98%
Change % Since Posting
-8.42
Change Since Posting
9.05
Price When Posted

Metrics

17.00
Target Price
9/ 10
Confidence
2-4 Weeks
Timeframe
catalyst icon
Earnings Per Share
catalyst icon
Financials
catalyst icon
Management
catalyst icon
Price to Earnings Ratio
catalyst icon
Dividend
catalyst icon
Other Catalyst

Access the latest tools and discussion channels with an account

reddit-sentiment

Reddit Sentiment
Analysis

portfolio-balancer

Portfolio Balancer
with brokerages

sec-dashboard

SEC Dashboard
with NLP

aiodd-ad
next